374
Views
14
CrossRef citations to date
0
Altmetric
Articles

Seasonal occurrence, removal and risk assessment of 10 pharmaceuticals in 2 sewage treatment plants of Guangdong, China

, , , &
Pages 458-469 | Received 10 May 2017, Accepted 15 Oct 2017, Published online: 10 Nov 2017
 

ABSTRACT

A long-term investigation, which covered 10 sampling campaigns over 3 years, was performed to evaluate the occurrence, removal and risk of 10 pharmaceuticals in 2 full-scale sewage treatment plants (STPs) in Guangdong, South China. Target pharmaceuticals except for clofibrate and ibuprofen were detected in every sample, with mean concentrations of 12.5–685.6 and 7.9–130.3 ng/L in the influent and effluent, respectively. Salicylic acid was the most abundant compound in both the influents and effluents in the two STPs. For most pharmaceuticals, the seasonal variation in the influent showed the highest concentrations in January and lowest concentrations in July due to their consumption and rainfall. Ibuprofen and fenoprofen presented high removal rates (>90%) and some of the targets such as gemfibrozil, mefenamic acid, tolfenamic acid and diclofenac were detectable with significantly higher mass loads in effluents than in influents. Studies of the five efficiently eliminated pharmaceuticals show that the primary treatment and secondary treatment contributed to most pharmaceutical removal, the anoxic tank made a negligible contribution to their elimination. According to the results produced from the calculation of the risk quotient, only diclofenac might pose a risk to the aquatic environment.

GRAPHICAL ABSTRACT

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This research was financially supported by the Special Investigation on Environment and Health in Key Areas of China [EH(2012)-07-03].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.